Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 December 2021 - 8:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of December 2021
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Purple Biotech Ltd. (the
“Company” or the “Registrant”) announced today that the Company’s Annual General Meeting of
Shareholders, on December 22, 2021 at 4:30 p.m. (Israel time) (the “Meeting”), was convened and adjourned, without
any business being conducted, due to lack of the required quorum. As stated in the Notice and Proxy Statement for the Meeting that was
attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange
Commission on November 10, 2021, the Meeting was therefore adjourned for one week, to the same time and place, i.e., Wednesday, December
29, 2021, at 4:30 p.m. (Israel time) at the Company offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel.
Incorporation by Reference
This Form 6-K, including
all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s
Registration Statement on Form S-8
filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478),
the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number
333-218538), the Registrant’s Registration Statement on Form
F-3, as amended, originally filed with the Securities and Exchange Commission on July 16,
2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file
number 333-230584), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration
file number 333-233795), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file
number 333-235327), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number
333- 238229), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number
333-238481) and each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on
July 10, 2020 (Registration file numbers 333-239807
and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
December 22, 2021
|
PURPLE BIOTECH LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Oct 2023 to Oct 2024